Hec1/Nek2 Mitotic Pathway Inhibitor I, INH1

A cell-permeable thiazolyl benzamide compound that directly binds Hec1 and disrupts Hec1/Nek2 complex formation, resulting in defective Hec1 kinetochores localization and cellular Nek2 destabilization/downregulation. Shown to induce a transient mitotic arrest in HeLa cultures and inhibit the proliferation of 10 breast cancer cell lines (GI₅₀ of 10-21 µM) as well as the cervical HeLa and colon HCT116 cancer lines, while exhibiting reduced potency against the noncancerous MCF10A line (GI₅₀ = 41 µM). Reported to suppress the MDA-MB-468-derived tumor growth (by ~53% and ~75% 3 wks after a 7-wk treatment period with 50 mg/kg and 100 mg/kg INH1, repectively, i.p.) in a murine breast cancer model in vivo.

Packaged under inert gas

Toxicity: Standard Handling (A)

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Wu, G., et al. 2008. Cancer Res.68, 8393.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany